CAI vs LH: How Caris Life Sciences and Labcorp Holdings Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: LH is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CAI and LH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CAI and LH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Caris Life Sciences, Inc. is an Irving, Texas based precision-medicine company that sequences tumors and blood to guide cancer treatment. Its core service is comprehensive molecular profiling: the MI Profile platform runs whole exome and whole transcriptome sequencing on tissue, while the Caris Assure platform does blood-based profiling, and newer assays extend into whole genome sequencing, minimal residual disease monitoring (Caris WGS MRD), hematologic profiling (Caris ChromoSeq) and multi-cancer early detection (Caris Detect). Alongside the clinical lab business, Caris licenses access to its multi-modal molecular and clinical database and runs research services for pharmaceutical partners, which is the second revenue line and the reason the company describes itself as an AI or TechBio company rather than a lab.

Full CAI guide

Labcorp Holdings is a leading US healthcare diagnostics company that runs clinical laboratory tests for physicians, hospitals, health systems, and patients, and also provides laboratory services to pharmaceutical and biotech firms running clinical trials. Its two reporting segments are Labcorp Diagnostics, the routine and specialty testing business that processes millions of patient samples, and Labcorp Biopharma Laboratory Services, which supports drug development with central-lab and early-development testing. Alongside domestic rival Quest Diagnostics, Labcorp is one of the two dominant independent lab networks in the country. The company spun off its clinical-trial contract-research organization, Fortrea, in 2023 to focus on core testing.

Full LH guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CAI drivers: Reimbursement-driven pricing (ASP); Volume growth and the shift to blood.
• LH drivers: Recurring diagnostics volume and scale; Hospital-lab acquisitions and outreach deals.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The clearest risk is reimbursement: a large share of recent revenue growth came from price rather than volume, and coverage decisions, rate resets, or payer pushback could reverse that quickly. For LH, labcorp's biggest risk is reimbursement pressure, since a large share of revenue depends on rates set by Medicare, Medicaid, and commercial payers, and legislated fee cuts under frameworks like PAMA can compress pricing.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CAI if you believe its drivers more; LH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CAI and LH guides.

CAI. Caris has no meaningful earnings multiple because it is only now reaching breakeven on a GAAP basis, so the market prices it on sales and on the durability of the pricing gains behind them. At roughly 5 times trailing revenue the stock is far below where it traded shortly after the June 2025 IPO, when the 52-week high reached ~$42.50 against a recent ~$16 price. Gross margin has widened toward the mid-60s percent range from the high-40s a year earlier, which is the other half of why losses collapsed.

LH. As of July 2026 Labcorp traded near $296 per share for a market cap around $24 billion, close to a 52-week high. The trailing P/E near 26x compresses to roughly 16x on 2026 adjusted EPS guidance, a valuation that sits below many healthcare peers. That reflects steady mid-single-digit revenue growth rather than rapid expansion, plus a modest dividend and buyback program.

Headline figures (approximate, August 2026): CAI shows revenue (ttm) ~$907M (+~100% YoY), q1 2026 revenue ~$216M (+~79% YoY), 2026 revenue guidance ~$1.00B to $1.02B (+~23% to 26%), q1 2026 adjusted ebitda ~$26M (fourth straight positive quarter); LH shows revenue (fy2025) ~$13.95 billion, revenue guidance (fy2026) ~$14.6-14.8 billion, net income (fy2025) ~$877 million, adjusted eps guidance (fy2026) ~$17.70-18.35.

CAI and LH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CAI and LH exposure against your real portfolio. It is not an investment adviser.